Nikolov I G, Joki N, Maizel J, Lacour B, Drüeke T B, Massy Z A
Inserm Unit 507, Necker Hospital, University of Paris V, Paris, France.
Kidney Int Suppl. 2006 Dec(105):S16-23. doi: 10.1038/sj.ki.5001994.
The number of chronic kidney disease (CKD) patients and related adverse outcomes has dramatically increased worldwide in the past decade. Therefore, numerous experimental and clinical studies have recently addressed the underlying mechanisms, in particular the marked increase in cardiovascular mortality. Hyperphosphatemia is a major problem in these patients with advanced stage of CKD. Its control by calcium-containing phosphate binders is effective, but at the price of potentially noxious calcium overload. Sevelamer hydrochloride is a phosphate binder that offers an effective control of hyperphosphatemia as calcium-rich binders but without increase of calcium load. Beyond the control of phosphate, sevelamer seems to exert pleiotropic effects which include the correction of lipid abnormalities and the clearance of some uremic toxins.
在过去十年中，全球慢性肾脏病（CKD）患者的数量及其相关不良后果急剧增加。因此，最近有大量实验和临床研究探讨了其潜在机制，尤其是心血管死亡率的显著上升。高磷血症是晚期CKD患者的一个主要问题。使用含钙磷结合剂对其进行控制是有效的，但代价是可能存在有害的钙超载。盐酸司维拉姆是一种磷结合剂，它能像富含钙的结合剂一样有效控制高磷血症，但不会增加钙负荷。除了控制磷之外，司维拉姆似乎还具有多种有益作用，包括纠正脂质异常和清除一些尿毒症毒素。
